(NASDAQ: COLL) Collegium Pharmaceutical's forecast annual revenue growth rate of 2.79% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.25%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.92%.
Collegium Pharmaceutical's revenue in 2025 is $664,283,000.On average, 3 Wall Street analysts forecast COLL's revenue for 2025 to be $24,290,368,769, with the lowest COLL revenue forecast at $24,186,999,480, and the highest COLL revenue forecast at $24,416,816,153. On average, 4 Wall Street analysts forecast COLL's revenue for 2026 to be $25,023,885,733, with the lowest COLL revenue forecast at $24,154,857,288, and the highest COLL revenue forecast at $25,384,296,132.
In 2027, COLL is forecast to generate $22,543,440,634 in revenue, with the lowest revenue forecast at $19,008,892,349 and the highest revenue forecast at $26,324,455,248.